RITUXAN®

(Rituximab)

Documentation

Patented
Approved 1997
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: ADCC
Target: CD20
Indication Category: Autoimmunity Cancer

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA